Valuation: Seres Therapeutics, Inc.

Market Cap 14.37M 13M 12M 10.86M 20.5M 1.35B 21.11M 144M 57.24M 722M 53.95M 52.8M 2.3B P/E 2026 *
-0.29x
P/E 2027 * -0.72x
Enterprise Value 14.37M 13M 12M 10.86M 20.5M 1.35B 21.11M 144M 57.24M 722M 53.95M 52.8M 2.3B EV / Sales 2026 *
7.19x
EV / Sales 2027 * 34.1x
Free-Float
88.8%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-6.00%
1 week-32.54%
Current month-20.34%
1 month-47.39%
3 months-70.13%
6 months-82.29%
Current year-90.52%
1 week 1.3
Extreme 1.3
2.05
1 month 1.3
Extreme 1.3
2.66
Current year 1.3
Extreme 1.3
16.42
1 year 1.3
Extreme 1.3
29.98
3 years 1.3
Extreme 1.3
41
5 years 1.3
Extreme 1.3
233.8
10 years 1.3
Extreme 1.3
770
Manager TitleAgeSince
Chief Executive Officer 70 2026-03-01
Chief Executive Officer 58 2025-07-31
President 51 2026-03-01
Director TitleAgeSince
Chairman 70 2026-03-01
Director/Board Member 50 2019-01-14
Director/Board Member 80 2015-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-82 0.0008%
8/17/26 Sell

Director

-263 0.0027%
8/17/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-6.00%-32.54%-91.19%-93.05% 14.37M
+1.10%-2.67%+62.79%+70.47% 68.45B
+0.56%+9.29%+15.97%+93.78% 61.31B
0.00%+0.57%+20.74%+98.81% 55.73B
-0.96%+7.41%+10.20%+108.91% 47.51B
-1.25%+2.35%+22.74%+38.34% 44.68B
-2.41%-0.73%+167.89%+794.72% 38.14B
+1.21%-2.56%+20.27%+52.81% 35.85B
-0.92%-0.94%+77.86%+54.74% 33.05B
-2.22%+8.56%-39.26%+397.14% 25.9B
Average -1.11%-0.42%+26.80%+161.67% 41B
Weighted average by Cap. -0.33%+2.84%+40.47%+163.81%

Financials

2026 *2027 *
Net sales 2M 1.81M 1.67M 1.51M 2.85M 188M 2.94M 20.04M 7.96M 101M 7.51M 7.35M 320M 422K 382K 352K 319K 602K 39.67M 620K 4.23M 1.68M 21.21M 1.58M 1.55M 67.51M
Net income -47.4M -42.86M -39.57M -35.81M -67.58M -4.46B -69.61M -475M -189M -2.38B -178M -174M -7.58B -52.83M -47.78M -44.1M -39.92M -75.33M -4.97B -77.59M -529M -210M -2.66B -198M -194M -8.45B
Net Debt - -
Projected Income Statement - Annual - Seres Therapeutics, Inc.
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
26-11-12 US$1.410 -6.00% 74,194
26-11-11 US$1.500 -3.85% 240,394
26-11-10 US$1.560 -8.24% 39,475
26-11-09 US$1.700 -14.14% 184,234
26-11-06 US$1.980 -5.26% 82,279
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Seres Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.410USD
Average target price
17.00USD
Spread / Average Target
+1,105.67%
  1. Stock Market
  2. Stocks
  3. MCRB Stock